Teva Pharmaceutical Industries (TEVA) Cash from Financing Activities: 2009-2025
Historic Cash from Financing Activities for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Sep 2025 value amounting to -$453.0 million.
- Teva Pharmaceutical Industries' Cash from Financing Activities was N/A to -$453.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.9 billion, marking a year-over-year change of. This contributed to the annual value of -$1.8 billion for FY2024, which is 6.38% up from last year.
- Teva Pharmaceutical Industries' Cash from Financing Activities amounted to -$453.0 million in Q3 2025, which was down 7,650.00% from $6.0 million recorded in Q2 2025.
- Teva Pharmaceutical Industries' 5-year Cash from Financing Activities high stood at $6.0 million for Q2 2025, and its period low was -$1.7 billion during Q1 2025.
- For the 3-year period, Teva Pharmaceutical Industries' Cash from Financing Activities averaged around -$589.5 million, with its median value being -$576.0 million (2023).
- Its Cash from Financing Activities has fluctuated over the past 5 years, first tumbled by 35,400.00% in 2023, then spiked by 100.62% in 2025.
- Over the past 5 years, Teva Pharmaceutical Industries' Cash from Financing Activities (Quarterly) stood at -$501.0 million in 2021, then slumped by 41.92% to -$711.0 million in 2022, then rose by 18.99% to -$576.0 million in 2023, then decreased by 17.01% to -$674.0 million in 2024, then surged by 100.62% to -$453.0 million in 2025.
- Its Cash from Financing Activities stands at -$453.0 million for Q3 2025, versus $6.0 million for Q2 2025 and -$1.7 billion for Q1 2025.